

www.tech-investor.com


**2nd Annual Boston Tech Investor BioBusiness &
Investor Network Seminar**

Evolving Approaches to Biotech Financing

*British Consulate General, One Memorial Drive, Suite 1500,
Cambridge, MA*

1 pm - 7:00pm, 14 November 2006

Sponsored by:



Agenda

Seminar Series: Evolving Approaches to Biotech Financing

British-Consulate General, One Memorial Drive, Cambridge, MA, 14 November 2006

Chairman: Dr Morris S Berrie, Managing Director, Tech Investor Limited

1:00 – 1:30pm Registration

1:30 – 1:35pm Introductory Remarks

1:35 – 2:00pm **KEYNOTE BIOTECH BUSINESS BRIEFING: Financing a Biotech Company**

Alexis Borisy, CEO, CombinatoRx

2:00 – 2:45pm **Panel 1: Keeping Good Companies going in difficult Financial Markets**

- Overview: Current financing strategies for private and public companies
- The true cost of financing: PIPEs versus registered deals versus secondary offerings
- Convertible debt deals
- Preferred stock sales to VC or institutional investors
- M&A alternatives

Jessica Chutter, Morgan Stanley; Geoff Davis, R&G; Peter Reikes, SG Cowen; Thomas Wiesel (tbc)

2:45 – 3:30pm **Panel 2: Moving beyond Traditional Venture Capital for Biotechnology**

- Business angel approaches to investing
- Strategies for first, second and third round financing
- Creating credible syndicates
- Creative deal structures to bridge valuation gaps
- Better approaches to down round financings

Dan Omsted, H&Q; Ed Mascioli, MPM; Michelle Doig, Abingworth; Steve Ferguson, Director Tech Transfer NIH

3:30 – 4:30pm Networking Breakout & Refreshments

4:30 – 5:15pm **Panel 3: Pharmaceutical licensing as a financial alternative**

- Thinking strategically about pharmaceutical licensing
- Issues worth negotiating
- Equity investment, credit facilities and other ways of obtaining needed capital

Marc Rubenstein, R&G; Chris Yochim, AstraZeneca; Jim Mcloughlin, Pfizer; Wyeth (tbc)

5:15 – 6:00pm **Panel 4: New Pathways to Liquidity**

- Managing the expectations of private equity investors
- Preparing for the transition from private to public company
- Delisting and Reverse Mergers
- Special purpose acquisition corporations (SPACs)
- Early IPOs as a way of accessing capital

Geoff Davis, R&G; Peter Reikes, SG Cowen; Jessica Chutter, Morgan Stanley; Thomas Wiesel (tbc); Alexis Borisy, CEO, CombinatoRx

6:00 – 7:30pm Investor Networking Cocktail Session